Multiple Sclerosis Research Reagents

Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system, affecting over 2.8 million people worldwide. Autoreactive T and B cells attack myelin sheaths, leading to demyelination, axonal injury, and progressive neurological disability. Clinical subtypes include relapsing-remitting MS (RRMS, ~85% at onset), secondary progressive MS (SPMS), and primary progressive MS (PPMS). The therapeutic landscape has expanded rapidly with anti-CD20 B cell depletion (ocrelizumab, ofatumumab), anti-integrin α4 therapies (natalizumab), S1P receptor modulators (fingolimod, siponimod), and emerging BTK inhibitors. Anti-drug antibody (ADA) monitoring is critical for biologics with immunogenicity risk, particularly natalizumab and ocrelizumab.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Multiple Sclerosis Research Reagents — key pathogenic pathways including CD20+ B cell-mediated demyelination, MOG autoimmunity, integrin alpha-4 lymphocyte trafficking, and GFAP astrocyte activation

Fig. 1 Key pathogenic pathways and research targets in multiple sclerosis. CD20+ B cell depletion, MOG-directed autoimmunity and demyelination, integrin α4-mediated lymphocyte CNS trafficking, and GFAP as an astrocyte activation biomarker. Key research targets highlighted in orange.

abinScience provides validated reference antibodies, anti-drug antibodies, ADA ELISA kits, and recombinant proteins for MS biologic research, including complete ADA toolkits for ocrelizumab and natalizumab (reference antibody + drug-level ELISA + ADA ELISA + neutralizing antibody ELISA). All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

CD20 (MS4A1) — Anti-CD20 B cell depletion has transformed MS treatment. Ocrelizumab (PPMS and RRMS) and ofatumumab (RRMS) selectively deplete CD20+ B cells while sparing plasma cells. abinScience offers a comprehensive ocrelizumab ADA toolkit: reference antibody, anti-ocrelizumab neutralizing and non-neutralizing recombinant antibodies (6 clones), drug-level ELISA, ADA ELISA, and neutralizing antibody ELISA. Additional CD20 reference antibodies include rituximab, obinutuzumab, ublituximab, and ofatumumab.
→ Browse CD20 antibodies, proteins & ELISA kits

Integrin α4 / Natalizumab — Natalizumab blocks integrin α4-mediated lymphocyte trafficking across the blood-brain barrier, reducing CNS inflammation in highly active RRMS. abinScience offers a complete natalizumab ADA toolkit: reference antibody, anti-natalizumab neutralizing and non-neutralizing recombinant antibodies (8 clones), drug-level ELISA, and ADA ELISA. ADA monitoring is particularly important for natalizumab, as neutralizing antibodies reduce drug efficacy and increase infusion reaction risk.
→ Browse Natalizumab antibodies & ELISA kits

MOG (Myelin Oligodendrocyte Glycoprotein) — MOG is expressed on the outermost surface of the myelin sheath and is a major autoantigen in MS. The anti-MOG recombinant antibody clone 8-18C5 (cross-reactive with human, mouse, and rat MOG) is widely used in experimental autoimmune encephalomyelitis (EAE) models. Available with fluorescent conjugates (FITC, PE, APC, PerCP) for flow cytometric analysis of demyelination and remyelination.
→ Browse MOG antibodies & proteins

GFAP (Glial Fibrillary Acidic Protein) — GFAP is an intermediate filament protein released by activated astrocytes during neuroinflammation. Serum GFAP is emerging as a biomarker for astrocyte pathology and progressive MS. Anti-GFAP polyclonal and recombinant antibodies (multiple clones including SAA0567, N206B/9R, H8/E9) support IHC, WB, and immunoassay development for neuroinflammation research.
→ Browse GFAP antibodies & proteins

IL-17A — IL-17A is a key effector cytokine of Th17 cells driving neuroinflammation and blood-brain barrier disruption in MS. Anti-IL-17A reference antibodies (bimekizumab, secukinumab, ixekizumab, netakimab) and recombinant IL-17A proteins support Th17 functional assays, cytokine profiling, and mechanism-of-action studies for emerging IL-17-targeting therapies.
→ Browse IL-17A antibodies & proteins

References

1. Hauser SL, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. DOI

2. Reich DS, et al. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180. DOI

3. Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622-1636. DOI